Haematology 2018

CAR19: challenges

▪ Bespoke individualised therapies – complex logistics

▪

Automated manufacture

▪

Expensive

▪

Allogeneic CAR-T

▪

Antigen escape relapses

▪ Targeting multiple antigens – single CAR construct, multiple CAR constructs, multiple cellular products

▪

Clinical challenges

▪

Durability of responses?

▪ Defining cell dose, optimal lymphodepletion

▪ Positioning in overall treatment pathway

▪ Optimal approach to limit or manage toxicities